Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Puma Biotech (PBYI) Tops Q4 EPS by 15c
February 25, 2021 5:30 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.14), $0.15 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.6 million versus the consensus estimate of $52.79 million.
During the fourth quarter of 2020 Puma continued to be negatively impacted by the challenges of COVID-19; however, we were pleased to be able to achieve NERLYNX revenues that were within the previously stated guidance, said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. Our year concluded with a number of positive clinical milestones for the Company, including the publication of ExteNET data in Clinical... More
